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Background: The SDHD gene encodes a subunit of the mitochondrial tricarboxylic acid cycle enzyme and tumor
suppressor, succinate dehydrogenase. Mutations in this gene show a remarkable pattern of parent-of-origin related
tumorigenesis, with almost all SDHD-related cases of head and neck paragangliomas and pheochromocytomas
attributable to paternally-transmitted mutations.
Methods: Here we explore the underlying molecular basis of three cases of paraganglioma or pheochromocytoma
that came to our attention due to apparent maternal transmission of an SDHD mutation. We used DNA analysis of
family members to establish the mode of inheritance of each mutation. Genetic and immunohistochemical studies
of available tumors were then carried out to confirm SDHD-related tumorigenesis.
Results: We found convincing genetic and immunohistochemical evidence for the maternally-related occurrence
of a case of pheochromocytoma, and suggestive evidence in a case of jugular paraganglioma. The third case appears
to be a phenocopy, a sporadic paraganglioma in an SDHD mutation carrier with no immunohistochemical or DNA
evidence to support a causal link between the mutation and the tumor. Microsatellite analysis in the tumor of patient 1
provided evidence for somatic recombination and loss of the paternal region of chromosome 11 including SDHD and
the maternal chromosome including the centromere and the p arm.
Conclusions: Transmission of SDHD mutations via the maternal line can, in rare cases, result in tumorigenesis.
Despite this finding, the overwhelming majority of carriers of maternally-transmitted mutations will remain
tumor-free throughout life.
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Paragangliomas of the head and neck (HNPGL) are rare
and often benign tumors that arise most commonly in
the carotid body, but also occur in the jugular bulb or
tympanic nerve and at the vagal bodies of the ganglions
of the vagal nerve [1]. HNPGLs are generally diagnosed
in adulthood and show mild symptoms, with a charac-
teristically slow tumor progression [2]. Pheochromocyto-
mas and abdominal paragangliomas are closely related
tumors that are associated with the sympathetic nervous* Correspondence: j.p.l.bayley@lumc.nl
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unless otherwise stated.system. They occur most commonly in the adrenal
medulla (as pheochromocytomas) but approximately 10-
20% arise elsewhere in the abdomen [3]. These non-
adrenal tumors are collectively referred to as ‘sympathetic
paragangliomas’ (sPGLs).
Succinate dehydrogenase (SDH) is a tetrameric mito-
chondrial enzyme that consists of two catalytic subunits,
SDHA and SDHB, and two membrane-anchoring sub-
units, SDHC and SDHD. SDH plays a central role in the
tricarboxylic acid cycle and the electron transport chain,
the two essential energy producing processes of the cell.
The last decade has seen the identification of muta-
tions in five SDH-related genes that cause hereditary
paraganglioma-pheochromocytoma syndrome, including
SDHD (chromosome 11q23) [4], SDHB (chromosomeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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(chromosome 11q12.2) [7], and SDHA (chromosome
5p15) [8].
Germline mutations of the SDHD gene show a ‘parent-
of-origin’ expression phenotype, with tumor development
occurring only when mutations are inherited via the pater-
nal line. This phenotype was originally interpreted as evi-
dence for ‘imprinted’ or allele-specific gene expression of
SDHD [9]. This phenomenon is not seen in the case of
SDHA, SDHB or SDHC gene mutations, which result in
tumor development regardless of the parental origin of
the mutation. The only other tumor suppressor genes
known to show a ‘parent-of-origin’ phenotype are the re-
cently described genes SDHAF2 and MAX, located on
chromosome 11q12.2 and 14q23, respectively [7,8,10].
Previous cases of tumor development related to mater-
nal transmission of an SDHD mutation include a 2008
report by Pigny et al. [11], which was later challenged as
a probable misdiagnosis [12], and more recent report by
Yeap et al. in which the authors presented genetic evi-
dence of maternal transmission [13].
Here we describe a patient with pheochromocytoma
and two patients with head and neck paraganglioma
who came to our attention due to tumor susceptibility
that was apparently maternally-related. We first inves-
tigated available family members to exclude the possi-
bility that the mutation could have been transmitted by
the biological father. We then analysed the loss of al-
leles of the SDHD gene in available tumors, we carried
out whole chromosome loss of heterozygosity (LOH)
analysis and finally, we analysed the expression of
SDHB in tumors, loss of which is a hallmark of tumors
related to succinate dehydrogenase dysfunction.
Methods
Patients
The patients described in this study carried a confirmed
pathogenic mutation in the SDHD gene, identified due
to a clinical diagnosis or to a family relationship to
known mutation carriers. Patients and family members
were seen at the relevant centers in Leiden or Rotterdam,
the Netherlands, or in Vancouver, Canada. Patients and
other currently unaffected family members known to be
mutation carriers underwent a full clinical assessment.
Written informed consent was obtained for DNA testing,
further analyses and publication of all results, according to
protocols approved by the Ethics Committees of the
Erasmus Medical Center, Rotterdam and the BC Cancer
Agency, Vancouver. Verbal informed consent was ob-
tained from patients seen at the LUMC, Leiden.
Haplotype analysis
DNA was isolated from heparinized whole blood accord-
ing to standard protocols. Analysis of haplotypes usingpolymorphic di-, and tetra nucleotide markers (microsat-
ellite markers) was performed following standard proce-
dures (details available upon request), using the markers
described in the results section. These markers were se-
lected based on location, and for probable informativity
due to a high reported heterozygosity index, from a cus-
tom database of 8100 markers based on the UniSTS and
Marshfield databases (available upon request).
Allele specific loss of SDHD
The loss of a specific parental allele of SDHD was deter-
mined by PCR and bi-directional Sanger sequencing of
the SDHD gene using standard procedures (primer de-
tails available upon request).
Loss of heterozygosity (LOH) analysis
Tumor sections (7um) were incubated overnight with
proteinase K at 60°C and DNA was isolated using the
Qiagen FFPE DNA kit (Qiagen Benelux B.V., Venlo, The
Netherlands) according to the manufacturer’s instruc-
tions. A selection of informative microsatellite markers
were analysed, as described in the results section. Paragan-
gliomas often remain histologically well-differentiated and
contain several types of normal cells that show expansion
under the influence of the chief cell fraction, the only neo-
plastic component of the tumor [14]. The presence and
expansion of these bystander cells means that loss of het-
erozygosity analysis is often contaminated by the presence
of DNA from these cell populations. We therefore used the
allelic imbalance ration of 0.7 or less as evidence for LOH
[15]. Microsatellite markers were analyzed on an ABI
3730 genetic analyzer and using Gene Marker software
(Soft Genetics, State College, PA 16803, USA), with
ABI GeneScan Rox 400 as internal size standards. LOH
of markers was calculated using the allelic imbalance
ratio: AIR = (Tumor1/Tumor2)/(Normal1/Normal2).
Ratios were based on results from the duplo analysis of
two separate DNA isolations from the tumor. Some
markers were either not informative in the patient or
did not perform well enough with tumor DNA to give a
reliable result. The remaining informative markers (n = 7)
were used in the analysis.
Pathology and (immuno)histochemistry
Sections from formalin-fixed paraffin embedded (FFPE)
tumor blocks were stained with hematoxylin & eosin
(H&E) using standard methods. An experienced neuroen-
docrine pathologist (RdK) evaluated slides and provided
or confirmed (patient 3) the histopathological diagnosis. A
recent and important development in the diagnosis of
SDH-related paraganglioma has been the application of
SDHB immunohistochemistry, which can reliably identify
and differentiate SDH-related tumors from tumors with
other causes regardless of which of the SDH genes is
Bayley et al. BMC Medical Genetics 2014, 15:111 Page 3 of 10
http://www.biomedcentral.com/1471-2350/15/111actually affected by a mutation [16]. SDHB immunohisto-
chemistry was carried out as described [16], using a
rabbit polyclonal primary SDHB antibody, HPA002868
(Sigma-Aldrich Corp; St Louis, MO, USA; 1:500).
Results and discussion
Our first patient (patient 1) was a young man who expe-
rienced increasing tiredness around the age of 16, but
without excessive transpiration or palpitations. The patient
also reported sudden weight gain and acute, localized
headaches. The evaluation of catecholamines showed
raised plasma concentrations of noradrenaline, adrenaline,
dopamine and raised urinary levels of normetanephrine.
Radiological examination (by CT) revealed a mass at the
level of the left kidney, and a positive octreotide scan
showed a suspicious accumulation at the left adrenal. A
tumor (70 × 60 × 40mm) was removed via adrenalectomy
and was confirmed as a pheochromocytoma with signs of
vasoinvasive growth. Although distant maternal relatives
of this patient have a history of paragangliomas and carry
a known pathogenic SDHD gene mutation, no immediate
maternal relative is affected, probably due to the inherit-
ance of the mutation via the maternal line for several gen-
erations. The paternal family had no known history of
paraganglioma. Due to the maternal inheritance of the
mutation, the patient was not immediately suspect for a
SDHD-related paraganglioma. The initial mutation ana-
lysis therefore focused on other genes including VHL (with
FISH analysis), RET, SDHB and SDHC. When all proved
to be negative, analysis of the SDHD gene was undertaken
and a heterozygous mutation identified in exon 3, the well-
known Dutch founder mutation, c.274G>T, p.Asp92Tyr,
also present in other family members. The patient, his
mother and his maternal grandmother all carried the
mutation (Figure 1a).
Analysis of microsatellite markers in patient 1 and four
other family members (Figure 1b) indicated that the pa-
tient indeed inherited a chromosome-wide, mutation-
associated haplotype from his mother, via the maternal
grandmother. The paternal chromosome, also represented
in the paternal grandmother and paternal aunt, was not
associated with a mutation of SDHD, indicating that the
patient inherited the mutation via the maternal line.
Review of H&E tumor sections from the pheochromo-
cytoma showed a typical morphology (Figure 1ci) and
anti-SDHB immunohistochemistry revealed specific loss
of SDHB protein expression in the adrenal medulla
(Figure 1cii).
Microdissection of tissue from the adrenal medulla,
followed by PCR analysis and sequencing of SDHD,
showed that the wild type allele (guanine (G) nucleotide –
arrow, Figure 2ai) is prominent in the DNA from blood
of patient 1 but is underrepresented in tumor DNA
(Figure 2aii), indicating loss of heterozygosity in thetumor. While not showing complete loss, this result is
typical of LOH in paraganglioma which show complex
and significant admixture of normal cells, largely main-
taining their normal tissue architecture and cellular
composition of normal cell types, which also proliferate
together with tumor cells.
As we wished to evaluate the extent and parental ori-
gin of chromosomal loss, tumor DNA was analyzed for
loss of heterozygosity using a selection of polymorphic
microsatellite markers. Tumor DNA from patient 1
showed chromosome-wide loss of heterozygosity, with
allelic imbalance ratios (AIR) of <0.7. Interestingly, ana-
lysis of the parental origin of the alleles showed only
partial loss of the paternal chromosome, with loss of ma-
ternal alleles on the p arm and centromeric q arm of
chromosome 11 (Figure 2ci). This result is most readily
explained by somatic recombination in a tumor progeni-
tor cell, followed by loss of a composite chromosome
consisting of the paternal (unmutated) allele of SDHD
and the maternal p arm of chromosome 11.
The second patient was also a young man, aged 17
at the time of diagnosis of bilateral paragangliomas.
The tumors were diagnosed using MRI and consisted
of a left-sided vagal tumor (30 × 40 × 45mm) encasing
the carotid artery and extending to the jugular bulb
(Figure 3a, arrow), and a very small right-sided carotid
body tumor. The vagal tumor was positive on octreo-
tide and DOPA-PET scan. Both tumors showed slow
growth on follow-up and have not been operated due
to risks of morbidity. In the three years following diag-
nosis the patient experienced episodes of loss of con-
sciousness, diagnosed as vasovagal syncope with an
uncertain relationship to the vagal tumor, and an ele-
vated 24hr urinary excretion of catecholamines without
signs or symptoms of catecholamine excess. MRI of the
abdomen revealed an 8mm nodule in the left adrenal,
which was removed by adrenalectomy and described as an
‘adrenal medullary hyperplasia or pheochromocytoma’ on
histopathologic examination.
Although the patient had several first and second-
degree relatives with paraganglioma, and a known
pathogenic mutation of SDHD (p.Asp92Tyr) in the ma-
ternal family, there was no known history of mutations
or paraganglioma on the father’s side (Figure 3b). As
the patient’s two younger siblings also carried the mu-
tation, both underwent ENT and endocrinological in-
vestigations but no tumors or signs of catecholamine
excess were found.
The analysis of genomic DNA from the patient and six
other family members using microsatellite markers con-
firmed inheritance of a maternal chromosome contain-
ing a minimal haplotype defined by the D11S1793 (allele
133) and D11SS4090 (allele 183) alleles, present in all
mutation carriers in the family (Figure 3c, yellow boxes).
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Figure 1 Patient 1 – pedigree and immunohistochemistry. a) An arrow indicates the proband. Filled boxes indicate paraganglioma and plus
or minus the SDHD mutation status. NT = not tested. b) Chromosome 11 haplotypes of family members. Microsatellite markers are shown with
genomic location (marker D11S4177 is close to the telomere of the p arm. Marker D11S4098 is close to the telomere of the q arm), and the
position of SDHD is indicated. Alleles in bright yellow blocks represent the probable disease haplotype, present in the proband, mother and
maternal grandmother. Other colors represent probable additional haplotypes in the family and possible recombinations; nd = not determined.
ci) SDHB immunohistochemistry of the pheochromocytoma, 25×. Inset, adrenal cortex positive for SDHB, 25×. cii) Detail of adrenal medulla, 200×,
with inset of positive cortex, 200×.
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analysis, the paternal haplotype could be defined by al-
leles present in the patient and siblings but not present
in any other family member. As both the patient and his
two siblings share a paternal haplotype including the
SDHD locus, a theoretical possibility exists that all three
offspring inherited the mutation from the father. Thiswould require the father to be a carrier of a mutation
identical to that of the mother. However, as all three
offspring also inherited a maternal mutation-bearing
haplotype and homozygous mutation of SDHD is in-
compatible with life, possible genetic mechanisms
allowing paternal inheritance are extremely improb-
able. The only likely explanation for these data, despite
D11S4127 - tumor DNA
D11S1793 – normal DNA
D11S1793 – tumor DNA
D11S4127 - normal DNA
Chr11
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Figure 2 Patient 1 – tumor analysis. a) Sanger sequencing of SDHD in normal (ai) and tumor (aii) DNA. Arrows indicate the relevant nucleotides in the
heterozygous patient. b) Typical profiles of microsatellite marker alleles showing loss of heterozygosity. Arrows indicate the allele lost. c) Table indicating
loss of microsatellite marker alleles and parental origin, with approximate positions indicated on an ideogram of chromosome 11.
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was inherited from the mother in all three siblings.
The only tumor tissue available for analysis from
this patient was an ‘adrenal medullary hyperplasia/
pheochromocytoma’. Although the adrenal medulla
showed clear signs of hyperplasia, this was insuffi-
ciently pronounced to allow a firm diagnosis. H&E
sections showed a typical adrenal structure with an
overprominent medulla (Figure 3d). Immunohisto-
chemical staining with an anti-SDHB antibody showed
clear loss of SDHB protein expression in the adrenal
medulla (Figure 3dii). However, sequencing analysis of
SDHD in normal and tumor samples provided no evi-
dence for loss of the wild type (normal) allele in the
tumor (Figure 3e), and microsatellite analysis showed
no loss of chromosome 11 in the tumor (Figure 3f ).
This result could be due to admixture of normal cells
with tumor cells, thereby masking loss of SDHD/
chromosome 11 in tumors cells – a phenomenoncommon in paragangliomas. Another possibility, and
one suggested by the profound loss of SDHB staining
in the adrenal medulla, is that a non-genetic mechan-
ism is mediating SDHD/SDHB loss in this tissue.
While inconclusive in terms of SDHD p.Asp92Tyr-me-
diated pathogenicity, these data do show that this case
of adrenal hyperplasia is SDH-related. However, speak-
ing conservatively, we cannot definitively conclude
that the patient’s p.Asp92Tyr mutation, a mutation
proven by its dominant role in paraganglioma patients
in the Netherlands and worldwide to be profoundly
pathogenic, is the cause of the adrenal hyperplasia in
this case. A firm conclusion will have to await the
availability of new tumor tissue.
The third patient, a female aged 37, first presented with a
feeling of fullness in the ears. A CT scan of the temporal
bones revealed a 5 mm mass in the left middle ear and
an enhancing lesion in the middle of the left ear cavity
was visible on MRI, consistent with a jugulotympanic
D11S923 – normal DNA
D11S923 – tumor DNA
D11S4076 – normal DNA
D11S4076 - tumor DNA
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Figure 3 (See legend on next page.)
Bayley et al. BMC Medical Genetics 2014, 15:111 Page 6 of 10
http://www.biomedcentral.com/1471-2350/15/111
(See figure on previous page.)
Figure 3 Patient 2 – pedigree, DNA and tumor analysis. a) MRI of the skull base in patient 2, showing a probable vagal body tumor (white
arrow). b) Pedigree of family 2 - arrow indicates the proband, filled boxes indicate paraganglioma, and plus or minus the SDHD mutation status.
NT = not tested. c) Chromosome 11 haplotypes of family members. Alleles in bright yellow blocks represent the likely disease haplotype, present
in all mutation carriers. Other colors represent probable additional haplotypes in the family and possible recombinations. The proband and
siblings all carry the disease haplotype. d) Histochemistry and immunohistochemistry: d1) HE staining of adrenal tumor, 25×, with inset 200×. d2)
SDHB immunohistochemistry of adrenal tumor, 25×. Inset, chromogranin A staining, 25×. e) Sanger sequencing of SDHD in normal and tumor
DNA. f) Typical profiles of microsatellite marker alleles showing no loss of heterozygosity.
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ation confirmed the diagnosis.
The patient had several maternal relatives with para-
gangliomas (Figure 4a) including the patient’s mother,
who had a left carotid body paraganglioma removed at
age 29 and was diagnosed with a right carotid body
paraganglioma at age 58 (treated with radiation). The
patient’s maternal aunt was diagnosed with a left jugu-
lotympanic paraganglioma at age 34, and treated for
recurrent disease at age 43. A maternal uncle, who died
aged 38, was reportedly diagnosed with renal cancer at
29 years old, followed by occurrence of a tumor of the
skull base at age 36, although neither diagnosis could
be confirmed. All of the patient’s siblings (two sisters
and one brother) were tumor-free and there were no
other known diagnoses of paraganglioma in the family.
Based on the lack of known disease in the paternal
family and a possible case of renal cancer, genetic testing
of the SDHB gene was initially offered to the patient.
This analysis failed to identify a mutation, but subse-
quent analysis of the SDHD gene resulted in the identifi-
cation of a heterozygous mutation, c.284 T>C, p.
Leu95Pro. Further testing in the family identified the
mutation in the proband’s mother, one sister, two cous-
ins (daughters of the patient’s maternal aunt with con-
firmed paraganglioma) and one of the cousin’s sons.
Two additional cousins in the same sibship tested nega-
tive for the mutation. All remaining individuals in the
family have not pursued genetic counseling to date.
Genomic DNA from three family members, all car-
riers of the p.Leu95Pro mutation, was available for
microsatellite analysis and all three were found to
share a common haplotype. Both daughters inherited a
common haplotype from their mother. A scenario of
paternal inheritance is effectively excluded in this pa-
tient by the differing paternal haplotypes carried by the
patient and her sister, and by the common maternal
haplotype (Figure 4b).
FFPE tumor tissue from patient 3 (Figure 3ci)
showed normal staining for SDHB, indicating retention
and normal expression of the protein (Figure 3cii).
DNA sequencing analysis also showed retention of the
wild type (normal) SDHD allele in the tumor (Figure 3d).
Microsatellite analysis of tumor DNA from patient 3(Figure 3e) showed an AIR of around 1.0, indicating
that there was no loss of heterozygosity of chromo-
some 11. The normal expression of the SDHB protein
and lack of evidence of genetic loss suggest that the p.
Leu95Pro mutation, despite being a well-established
pathogenic mutation, is not causative in this patient’s
tumor.
In this study we present genetic and functional evidence
supporting the bone fide maternal-related occurrence of a
case (patient 1) of pheochromocytoma; a case with both
an unequivocal clinical diagnosis and histological confirm-
ation. We also present a case (patient 2) of head and neck
paraganglioma with suggestive evidence for maternal-
related tumorigenesis.
The ‘parent-of-origin’ related tumor phenotype of SDHD
is one of the most unusual genetic manifestations in all of
cancer biology and remains poorly understood. While the
first recognition of this phenomenon immediately sug-
gested the involvement of a maternally-imprinted gene
[9], analysis of allele-specific expression in a variety of tis-
sues has shown biallelic expression [4,17]. The complete
constitutive silencing of one allele of SDHD is unlikely for
several reasons, not least due to the specific loss of the
maternal allele in SDHD-related paragangliomas, which is
counterintuitive if one assumes that this allele is already
completely inactivated by imprinting [18]. As patients with
SDHD-related paraganglioma carry paternally-inherited
mutations, a maternal imprint would result in a profound
deficiency of succinate dehydrogenase activity, a situ-
ation known to cause major developmental defects
even when residual enzyme activity is present [19].
Homozygous knockout of Sdhd in mice results in em-
bryonic lethality [20,21].
A ‘parent-of-origin’ tumor phenotype is shared by a
closely related gene, the recently identified succinate
dehydrogenase assembly factor, SDHAF2. This gene
encodes a protein involved in the addition of the
flavin-adenine dinucleotide prosthetic group to form
the active SDHA flavoprotein [7]. Although less central
to SDH function than the SDHB and SDHC genes, both
located on chromosome 1, SDHAF2 shares one import-
ant characteristic with SDHD; both are located on
chromosome 11. Chromosome 11 also harbors the
main concentration of imprinted genes in the human
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Figure 4 (See legend on next page.)
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Figure 4 Patient 4 – pedigree, DNA and tumor analysis. a) Arrow indicates the proband, filled boxes indicate paraganglioma, plus or minus
the SDHD mutation status, and question marks indicate suspicious but unconfirmed phenotypes. b) Chromosome 11 haplotypes of immediate
family. Microsatellite markers are shown with genomic location. Alleles in yellow blocks represent the probable disease haplotype. c) Histochemistry
and immunohistochemistry: c1) HE staining of JT PGL, 25×. c2) SDHB immunohistochemistry, 25×. d) Sanger sequencing of SDHD in normal (e1) and
tumor (e2) DNA. e) Typical profiles of microsatellite marker alleles showing no loss of heterozygosity.
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expressed exclusively from the paternal or maternal
chromosome and the opposite allele silenced by epi-
genetic mechanisms.
Functional loss of the maternal copy of chromosome
11 is a hallmark of SDHD-linked paragangliomas
[18,22-24] and has led to the proposal that tumorigen-
esis occurs only when a paternally-transmitted muta-
tion of SDHD and loss of the remaining non-imprinted
maternal allele is accompanied by loss of a maternally-
expressed imprinted modifier gene. Due to their com-
mon chromosomal location, SDHD (or SDHAF2) and
an imprinted modifier can be targeted in a single gen-
etic event involving whole chromosome loss. This
‘SDHD-imprinted modifier gene’ hypothesis has be-
come known as the ‘Hensen Model’ [11,12,18]. Other
studies have suggested that loss of the maternal copy
of chromosome 11 may also be a factor in both spor-
adic pheochromocytomas and those related to muta-
tions of the Von Hippel-Lindau (VHL) gene, located on
chromosome 3 [25,26].
The ‘Hensen Model’ is relevant to the data presented
here as it may explain the somatic recombination seen
in the tumor of patient 1. This is an unusual event in it-
self and has only previously been described in one case
of paraganglioma [13]. Hensen and colleagues (2004)
predicted exactly the scenario now observed; “When the
SDHD mutation is maternally-transmitted, at least two
events caused by different chromosomal mechanisms
will be required… namely loss of the paternal wild-type
SDHD allele by, for example, mitotic recombination,
followed by loss of the recombined paternal chromo-
some containing the paternal 11q23 region and the ma-
ternal 11p15 region”.
The third patient represents the first reported case of
a phenocopy in PGL. A phenocopy in a family with a
hereditary tumor burden is an individual with a tumor
that is unrelated to the familial genotype, a frequent
phenomenon in families with common tumors such as
those of the breast or colon. This case also serves to
demonstrate that causality cannot be taken for granted,
even in patients with well-described pathogenic muta-
tions. To rule out misdiagnosis of the tumor, morph-
ology and immunohistochemical characteristics were
closely scrutinized both initially, and subsequent to the
evaluation of the genetic and SDHB immunohistochemicalanalysis results. Two independent pathologists confirmed
the diagnosis of jugulotympanic paraganglioma, and all
morphological and histochemical indicators supported this
conclusion.Conclusions
At least two cases of maternally-inherited SDHD-related
tumor susceptibility have now been described (this study
and [13]). This presents genetic counselors with a chal-
lenge, as it is now no longer possible to unequivocally state
that a carrier of a maternally-transmitted mutation will
never develop a tumor. Despite this development, we con-
sider the increase in risk represented by these reports to be
negligible. Carriers of maternally-inherited SDHD muta-
tions can still be assured that their lifetime risk is not sig-
nificantly different to non-mutation carriers. Whether this
report will stimulate clinicians to re-evaluate carriers of
maternally-inherited mutations, leading to the recognition
of further cases, remains to be seen.
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